Moving cellular therapies to the front line for Ph(+) B cell acute lymphoblastic leukemia Editorial
| Authors: | Feng, Y.; Leveille, E.; Park, J. H.; Müschen, M. |
| Title: | Moving cellular therapies to the front line for Ph(+) B cell acute lymphoblastic leukemia |
| Abstract: | Chemotherapy-free regimens have gained increasing attention as frontline treatments for B cell acute lymphoblastic leukemia (B-ALL) due to the limitations of chemotherapy. Zhang and colleagues conducted the first trial incorporating CAR-T into Ph+ B-ALL frontline treatment, demonstrating remarkable efficacy and tolerability.1 © 2025 The Author(s) |
| Keywords: | adult; cancer chemotherapy; clinical article; aged; unclassified drug; overall survival; note; follow up; cancer immunotherapy; dexamethasone; cytotoxicity; abelson kinase; dasatinib; cancer specific survival; long term care; outcomes research; cell therapy; vindesine; zinc finger protein; cd22 antigen; first-line treatment; preclinical study; blinatumomab; ponatinib; human; male; female; b cell acute lymphoblastic leukemia; ikaros family zinc finger protein 1 |
| Journal Title: | Cell Reports Medicine |
| Volume: | 6 |
| Issue: | 7 |
| ISSN: | 2666-3791 |
| Publisher: | Cell Press |
| Date Published: | 2025-07-15 |
| Start Page: | 102184 |
| Language: | English |
| DOI: | 10.1016/j.xcrm.2025.102184 |
| PROVIDER: | scopus |
| PMCID: | PMC12281393 |
| PUBMED: | 40669449 |
| DOI/URL: | |
| Notes: | Note -- Source: Scopus |
